NANOG and neoplasm: Western blot analysis of ex vivo isolated tumors at day 35 after challenge demonstrated decreased levels of pFGFR, pERK and NANOG proteins among mice that received 0.5 mg/kg of SSR128129E (Figure 8k), demonstrating achievement of successful in vivo delivery of SSR128129E to the tumor.